DBV Technologies Announces Presentation from NIAID-sponsored CoFAR6 Phase II Trial Reaffirming Viaskin(R) Peanut Safety and Efficacy

DBV Technologies (NASDAQ:DBVT) announced the presentation of results from CoFAR6, a Consortium of Food Allergy Research (CoFAR) study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), showing that treatment with Viaskin® Peanut was observed to be safe and well-tolerated, and led to statistically significant desensitization in trial subjects.
According to the news:

The Viaskin Peanut patch is DBV Technologies’ lead product candidate, based on epicutaneous immunotherapy (EPIT®), a proprietary technology platform that can deliver biologically active compounds to the immune system through the immune cells of intact skin.

Dr. Pierre-Henri Benhamou, Chairman and Chief Executive Officer of DBV Technologies commented:

We are thankful for NIAID’s support of our approach to finding a potential treatment for peanut allergy. CoFAR6 provides us with additional, independent confirmation  of our own Viaskin Peanut Phase IIb findings, while also increasing our understanding of the mechanism of action of epicutaneous immunotherapy, which we believe is a potential patient-centered solution for those suffering from food allergies.

Click here to view the full press release.